Rani George, MD, PhD
Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Associate Professor of Pediatrics, Harvard Medical School
Image
Rani George, MD, PhD
Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Associate Professor of Pediatrics, Harvard Medical School
Medical Services
Education
Medical School
A.M. Dogliotti College of Medicine, University of Liberia
Monrovia
Liberia
Internship
John F. Kennedy Memorial Medical Center
Indio
CA
Residency
Pediatrics
Boston Combined Residency Program (BCRP)
Boston
MA
Residency
The Royal Victoria Infirmary
Newcastle-upon-Tyne
England
Fellowship
Pediatric Hematology -Oncology
Boston Children's Hospital/Dana-Farber Cancer Institute
Boston
MA
Fellowship
Pathology
Harvard Medical School
Boston
MA
Professional History
Dr George received her MD from the University of Liberia and her PhD from the University of Newcastle-upon-Tyne, UK. She completed clinical training in pediatrics and hematology/oncology at the Royal Victoria Infirmary, Newcastle-upon-Tyne, Boston Childrens Hospital and DFCI, and post-doctoral research at Harvard Medical School and DFCI. Her laboratory focuses on identifying molecular targets in cancer cells that can be translated into novel therapies with special emphasis on the pediatric solid tumor neuroblastoma. The translational research program in her laboratory integrates cancer biology, preclinical drug development and clinical trials targeting molecular aberrations in neuroblastoma and other pediatric solid tumors.
Publications
A drug that induces the microRNA miR-124 enables differentiation of retinoic acid-resistant neuroblastoma cells. View Abstract
Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology. View Abstract
Novel miRNA-inducing drugs enable differentiation of retinoic acid-resistant neuroblastoma cells. View Abstract
Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation. View Abstract
The MYCN 5' UTR as a therapeutic target in neuroblastoma. View Abstract
CKLF instigates a "cold" microenvironment to promote MYCN-mediated tumor aggressiveness. View Abstract
Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch. View Abstract
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. View Abstract
Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma. View Abstract
Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration. View Abstract
Giotto: a toolbox for integrative analysis and visualization of spatial expression data. View Abstract
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. View Abstract
Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras. View Abstract
MYCN amplification and ATRX mutations are incompatible in neuroblastoma. View Abstract
Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor. View Abstract
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma. View Abstract
BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells. View Abstract
JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma. View Abstract
CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. View Abstract
mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. View Abstract
Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). View Abstract
Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. View Abstract
Super-Enhancer-Driven Transcriptional Dependencies in Cancer. View Abstract
Cbx3/HP1? deficiency confers enhanced tumor-killing capacity on CD8+ T cells. View Abstract
Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. View Abstract
Targeting ALK: The Ten Lives of a Tumor. View Abstract
Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. View Abstract
TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. View Abstract
Seek and Ye Shall Find: Subclonal Anaplastic Lymphoma Kinase Mutations. View Abstract
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. View Abstract
Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. View Abstract
CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. View Abstract
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. View Abstract
Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma. View Abstract
Distinct neuroblastoma-associated alterations of PHOX2B impair sympathetic neuronal differentiation in zebrafish models. View Abstract
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. View Abstract
Promising therapeutic targets in neuroblastoma. View Abstract
Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. View Abstract
Tumor histology during induction therapy in patients with high-risk neuroblastoma. View Abstract
Emerging importance of ALK in neuroblastoma. View Abstract
Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors. View Abstract
Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. View Abstract
Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study. View Abstract
Pharmacotherapy of neuroblastoma. View Abstract
Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. View Abstract
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. View Abstract
Activating mutations in ALK provide a therapeutic target in neuroblastoma. View Abstract
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. View Abstract
Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. View Abstract
Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. View Abstract
Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study. View Abstract
High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. View Abstract
Zebrafish foxd3 is selectively required for neural crest specification, migration and survival. View Abstract
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. View Abstract
Association between congenital cardiovascular malformations and neuroblastoma. View Abstract
Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. View Abstract